PaxMedica Holds Meeting of Scientific Advisory Board
March 20 2023 - 8:00AM
via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage
biopharmaceutical company focusing on the development of novel
anti-purinergic drug therapies (“APT”) for the treatment of
disorders with intractable neurologic symptoms, today announced
that it held a Scientific Advisory Board meeting on March 10-12,
2023. A number of new members have been added to the board,
which consists of many key opinion leaders in autism spectrum
disorder (ASD) in the United States including:
- Dr Robert Naviaux, Professor of
Medicine, Pediatrics, and Pathology, at the University of
California, San Diego
- Dr. Robert Findling, Chair of the
Department of Psychiatry, at Virginia Commonwealth University
School of Medicine
- Dr. Alice Mao, Professor of
Psychiatry and Behavioral Sciences, at Baylor College of
Medicine
- Dr. Constance Smith-Hicks,
Associate Professor of Neurology at Johns Hopkins University and
neurologist and research scientist at the Kennedy Krieger
Institute
- Dr. Andrew J. Cutler, Clinical
Associate Professor of Psychiatry, SUNY Upstate Medical University
and Chief Medical Officer, Neuroscience Education Institute
- Dr. Vladimir Maletic, Clinical
Professor, Neuropsychiatry and Behavioral Science, University of
South Carolina School of Medicine
- Dr. Michael Aman, Professor
Emeritus, The Ohio State University Department of Psychology
- Dr. Rakesh Jain, Clinical
Professor, Department of Psychiatry Texas Tech University School of
Medicine - Permian Basin
The meeting was hosted by PaxMedica’s Chief Medical Officer,
Stefan Schwabe, MD, PhD, who commented, “We convened some of the
country’s leading experts in autism spectrum disorder in support of
our efforts to bring suramin to the next phase of clinical trials.
We continue to be very excited about studying a product for the
potential treatment of the core symptoms of autism spectrum
disorder.”
Dr. Robert Naviaux added, “At the scientific advisory board
meeting this weekend, experts from many different areas of medicine
came together to share their thoughts on how suramin may work in
ASD and how it might work in several other complex disorders. What
emerged was a clear vision for the next steps needed to test
suramin in autism. This is expected to be done in a series of
international, multicenter, clinical trials that are projected to
begin in 2024.”
About PaxMedica
PaxMedica is a clinical stage biopharmaceutical company focusing
on the development of anti-purinergic drug therapies (“APT”) for
the treatment of disorders with intractable neurologic symptoms,
ranging from neurodevelopmental disorders, including Autism
Spectrum Disorder (“ASD”), to Myalgic Encephalomyelitis/Chronic
Fatigue Syndrome (“ME/CFS”), a debilitating physical and cognitive
disorder believed to be viral in origin and now with rising
incidence globally due to the long term effects of SARS-CoV-2
(“COVID-19”). One of PaxMedica’s primary points of focus is the
development and testing of its lead program, PAX-101, an
intravenous formulation of suramin, in the treatment of ASD and the
advancement of the clinical understanding of using that agent
against other disorders such as ME/CFS and Long COVID-19 Syndrome,
a clinical diagnosis in individuals who have been previously
infected with COVID-19. For more information, please visit:
www.paxmedica.com
Forward-Looking Statements
This press release contains “forward-looking statements.”
Statements contained in this press release other than statements of
historical fact are forward-looking statements, including but not
limited to statements regarding our anticipated development and
operating plan, achievement of anticipated milestones, planned
research and development efforts and other matters regarding
the Company’s business strategy, use of capital, and plans and
objectives for future operations. Forward-looking statements
reflect our current view about future events. These forward-looking
statements involve known and unknown risks and uncertainties and
are based on the Company’s current expectations and projections
about future events that the Company believes may affect its
financial condition, results of operations, business strategy and
financial needs. Investors can identify these forward-looking
statements by words or phrases such as “may,” “will,” “could,”
“expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,”
“believe,” “is/are likely to,” “propose,” “potential,” “continue”
or similar expressions. The Company undertakes no obligation to
update or revise publicly any forward-looking statements to reflect
subsequent occurring events or circumstances, or changes in its
expectations, except as may be required by law. Although the
Company believes that the expectations expressed in these
forward-looking statements are reasonable, it cannot assure you
that such expectations will turn out to be correct, and the Company
cautions investors that actual results may differ materially from
the anticipated results and encourages investors to review other
factors that may affect its future results in the Company’s
registration statement, most recent quarterly reports, and other
filings with the U.S. Securities and Exchange Commission.
Contacts:
ir@paxmedica.com
Stephanie PrincePCG Advisorysprince@pcgadvisory.com(646)
863-6341
PaxMedica (NASDAQ:PXMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
PaxMedica (NASDAQ:PXMD)
Historical Stock Chart
From Apr 2023 to Apr 2024